Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan A Pennell

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2022
Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung CancerNathan A Pennell
Journal of Oncology Practice|September 4, 2012
Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of CrizotinibNathan A Pennell
Cleveland Clinic Journal of Medicine|May 23, 2012
Selection of chemotherapy for patients with advanced non-small cell lung cancerNathan A Pennell
Seminars in Oncology|October 20, 2015
Understanding the Rationale for Immunotherapy in Non-Small Cell Lung CancerNathan A Pennell
JAMA Oncology|February 4, 2021
Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung CancerNathan A Pennell
Translational Lung Cancer Research|March 26, 2015
Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progressNathan A Pennell
Clinical Lung Cancer|July 5, 2011
Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancerNathan A Pennell
JAMA Oncology|March 18, 2016
PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung CancerNathan A Pennell
The American Journal of Managed Care|June 15, 2012
Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinibNathan A Pennell
Oncology (Williston Park, N.Y.)|December 9, 2010
Time to move beyond clinical and pathologic classification of BACNathan A Pennell, Ramaswamy Govindan
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2022
Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non-Small-Cell Lung CancerNathan A Pennell
Journal of Oncology Practice|September 4, 2012
Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of CrizotinibNathan A Pennell
Cleveland Clinic Journal of Medicine|May 23, 2012
Selection of chemotherapy for patients with advanced non-small cell lung cancerNathan A Pennell
Seminars in Oncology|October 20, 2015
Understanding the Rationale for Immunotherapy in Non-Small Cell Lung CancerNathan A Pennell
JAMA Oncology|February 4, 2021
Adjuvant Targeted Therapy for Patients With Epidermal Growth Factor Receptor-Mutant Lung CancerNathan A Pennell
Translational Lung Cancer Research|March 26, 2015
Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progressNathan A Pennell
Clinical Lung Cancer|July 5, 2011
Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancerNathan A Pennell
JAMA Oncology|March 18, 2016
PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung CancerNathan A Pennell
The American Journal of Managed Care|June 15, 2012
Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinibNathan A Pennell
Oncology (Williston Park, N.Y.)|December 9, 2010
Time to move beyond clinical and pathologic classification of BACNathan A Pennell, Ramaswamy Govindan
Pageof 12